Enclomiphene: animal studies vs. the human evidence

Last updated 2026-07-27

What did the original animal studies on enclomiphene actually show?

The foundational work on clomiphene's two isomers (enclomiphene and zuclomiphene) goes back to the 1960s and 70s, well before anyone was marketing enclomiphene on its own. Researchers used rat and rabbit models to figure out that clomiphene wasn't one drug acting one way. It was a mixture of a fast-clearing isomer (enclomiphene, also called en-clomiphene or trans-clomiphene) and a slow-clearing one (zuclomiphene, the cis isomer) with different receptor behaviors ^[1]. In rodent studies, enclomiphene showed estrogen-receptor antagonist activity, basically blocking estrogen from telling the hypothalamus to slow down. Zuclomiphene, by contrast, behaved more like a weak estrogen agonist in some of that early animal work. That split is the whole reason enclomiphene got pulled out and studied on its own instead of just using clomiphene citrate for men. Dog studies mattered too. Canine models were used in some of the early pharmacology work because dogs have a hypothalamic-pituitary-gonadal axis that responds in broadly similar ways to primates for gonadotropin signaling, though the correspondence isn't perfect. None of this animal work proves what happens in a grown man on a daily dose for a year. It proves the mechanism is plausible and worth testing in people, which is exactly what happened next. It's worth being honest about the limits here: rodent HPG axis kinetics, dosing intervals, and estrogen receptor subtype distribution are not identical to human physiology. The animal data set the hypothesis. It didn't close the case.

What is the actual human evidence for enclomiphene raising testosterone?

The strongest human data comes from the Androxal development program, run by Repros Therapeutics, which pushed enclomiphene through phase 2 and phase 3 trials aimed at FDA approval for men with secondary hypogonadism. Across these trials, enclomiphene citrate raised serum testosterone into the normal range in the large majority of treated men, generally performing comparably to topical testosterone gel on that single endpoint ^[2]. A 2012 clinical study published in the Journal of Sexual Medicine found that enclomiphene citrate significantly increased total testosterone and luteinizing hormone in hypogonadal men while transdermal testosterone suppressed LH and shrank testicular volume markers over the same period ^[3]. That's the core data point everyone cites, and it holds up: the mechanism (stimulating the pituitary via reduced estrogen feedback, rather than replacing testosterone from outside) produces a genuinely different hormonal signature than TRT. Smaller studies and case series since then, including work looking at enclomiphene as monotherapy for men wanting to avoid injections, have generally replicated the direction of that effect: testosterone up, LH and FSH preserved or increased, sperm parameters not tanking the way they do on exogenous testosterone. Sample sizes in most of these are small, often under 150 men, and follow-up is usually 3 to 6 months, not years. For a longer breakdown of individual trials and their numbers, see our page on Enclomiphene Direct human studies.

Why did enclomiphene (Androxal) never get FDA approval?

This is the detail a lot of marketing pages skip. Androxal, the branded enclomiphene product Repros Therapeutics developed, went through multiple FDA review cycles and did not reach approval as a standalone prescription drug. The FDA's own drug database confirms there is no approved enclomiphene product; searching Drugs@FDA for enclomiphene returns no approved application ^[4]. Repros Therapeutics' regulatory filings and investor disclosures documented the specific sticking points, which centered on questions about long-term safety data, the durability of the testosterone response, and how the FDA weighed prostate-specific antigen and other safety monitoring data submitted across the trial program ^[5]. The company was acquired and the Androxal program was effectively shelved rather than resubmitted successfully. This matters practically because it means every dose of enclomiphene sold in the US today comes from a compounding pharmacy operating under a prescription, not from a manufacturer with an FDA-approved label, dosing instructions, and post-market surveillance requirement. Compounded enclomiphene is legal to prescribe under state pharmacy law and FDA's compounding framework, but it is not the same regulatory category as an approved drug, and that distinction should shape how much certainty you attach to any specific dose or claim.

How is enclomiphene different from clomiphene?

Clomiphene citrate (brand name Clomid) is not enclomiphene. Clomiphene is a roughly 62:38 mixture of two isomers, zuclomiphene and enclomiphene, and the two behave differently in the body ^[1]. Enclomiphene is the isomer that acts mostly as an estrogen receptor antagonist at the hypothalamus, which is the piece that drives the LH/FSH increase and downstream testosterone rise. Zuclomiphene clears more slowly, accumulates with repeated dosing, and has a more mixed agonist/antagonist profile that some researchers have linked to a larger share of the mood-related and visual side effects reported with clomiphene use in men ^{[1] [3]}. FDA-approved clomiphene citrate is labeled for female infertility, not male hypogonadism; any male use of clomiphene or enclomiphene is off-label or via compounding, and neither drug carries an FDA indication for raising testosterone in men. The practical reason people seek out enclomiphene specifically, rather than generic clomiphene, is the isomer-specific mechanism and a side-effect profile that trial data suggest is somewhat cleaner, though head-to-head long-term human comparisons remain limited ^[3].

Does enclomiphene actually preserve fertility better than TRT?

This is the central question for most men looking at this drug, and the honest answer is: the mechanism strongly supports it, and the short-term human data backs that up, but nobody has a large long-term trial proving specific fertility outcomes like pregnancy rates. Exogenous testosterone (injections, gels, pellets) shuts down the hypothalamic-pituitary-gonadal axis by signaling the brain that testosterone levels are already high. LH and FSH drop, the testes stop producing their own testosterone and sperm, and testicular volume shrinks over months of use. This is well documented and is exactly why TRT is a recognized cause of secondary infertility in men on long-term therapy. Enclomiphene works upstream of that. By blocking estrogen receptors at the hypothalamus, it removes the negative feedback signal, so LH and FSH go up rather than down. That in turn stimulates the testes to make more of their own testosterone, and because FSH signaling is preserved or increased rather than suppressed, spermatogenesis is not shut down the way it is on TRT ^[3]. Trial data from the enclomiphene program showed testicular volume and sperm-relevant hormone markers held up meaningfully better than in the testosterone-gel comparison arm ^{[2] [3]}. What the evidence does not include: multi-year studies tracking actual pregnancy rates in couples where the male partner used enclomiphene, or large-scale semen analysis data across diverse baseline fertility situations. If preserving fertility while on therapy is the priority, and you want the details laid out study by study, that's covered on our Enclomiphene Direct human studies page. Anyone with an existing fertility concern should be working with a reproductive urologist, not extrapolating from a hormone panel alone.

What do the human trials say about side effects and safety?

Reported side effects in the enclomiphene trials include headache, in some studies elevated liver enzymes, mood changes, and in a minority of cases visual disturbances similar to what's reported with clomiphene, though at generally lower rates given enclomiphene's isomer-specific profile ^{[2] [3]}. Rates of these effects varied across trial arms and were generally described as mild to moderate. One monitoring point that shows up consistently in the trial literature is PSA and hematocrit tracking, standard for any therapy that raises testosterone, since elevated testosterone can raise hematocrit (thickening the blood) and there's ongoing monitoring interest around prostate markers with any androgen-axis therapy ^[2]. This is not unique to enclomiphene; it's the same panel a doctor should be running for anyone on TRT too. What's genuinely thin is long-term cardiovascular outcome data. The big testosterone-and-cardiovascular-risk debate that has played out in the TRT literature over the past decade (including the TRAVERSE trial, a large randomized study of testosterone replacement and cardiovascular safety) has no equivalent-scale study for enclomiphene ^[6]. That doesn't mean there's a known risk. It means the question hasn't been asked at that scale yet. Drug interactions are another area where the compounded, off-label status matters, since there's no FDA label spelling out interaction warnings the way there would be for an approved drug. If you're on other medications, this is worth reviewing directly; see Enclomiphene Direct drug interactions for specifics.

How strong is the evidence, really, ranked from animal to human?

It helps to lay this out plainly, because marketing copy tends to blur the line between mechanism, animal proof-of-concept, and confirmed human outcomes. | Evidence tier | What it shows | Strength | Key gap |

Since enclomiphene isn't FDA-approved, what does that mean for sourcing?

Because Androxal never reached approval, there is no manufacturer producing an FDA-approved enclomiphene tablet with a standardized label. Everything available in the US comes from a licensed compounding pharmacy filling a prescription written by a doctor or nurse practitioner, typically after a telehealth consult and bloodwork. Compounding pharmacies operate under different oversight than manufacturers, governed by state pharmacy boards and, for pharmacies compounding at scale, FDA's 503A/503B framework rather than the New Drug Application process . That's a legitimate, legal path to access the drug, but it also means potency consistency and quality control depend heavily on which specific pharmacy fills the prescription, not on a single FDA-reviewed manufacturing standard. Enclomiphene Direct works through a provider-reviewed process and names its fulfilling pharmacy partner rather than compounding anything in-house, which is the model to look for: a real prescriber reviewing labs, and a named, licensed pharmacy doing the actual compounding. If you're comparing that model against buying from a research-chemical supplier with no prescription and no pharmacy oversight, the difference in quality assurance and legal footing is significant; see Enclomiphene Direct compounding pharmacy vs research supplier for that comparison in detail.

How does enclomiphene compare to other fertility-preserving TRT options like hCG?

Enclomiphene isn't the only option for men who want testosterone support without shutting down the HPG axis. Human chorionic gonadotropin (hCG) is the other common route, and it works differently: hCG mimics LH directly, stimulating the testes to produce testosterone without going through the hypothalamus at all. Both approaches preserve testicular function better than exogenous TRT alone, but they're not interchangeable. hCG requires injections, is typically used alongside TRT in combination protocols (to keep the testes active while on injectable testosterone) rather than as a standalone testosterone-raising agent, and has its own cost and monitoring considerations. Enclomiphene is an oral tablet and works upstream, raising the body's own LH and FSH rather than replacing LH's action directly. For men who specifically want to avoid injections altogether, that's often the deciding factor. A full side-by-side on cost, administration, and use cases is on Enclomiphene Direct vs hcg.

What should someone starting enclomiphene actually expect, practically?

Expect bloodwork before starting (total and free testosterone, LH, FSH, estradiol, PSA, hematocrit, at minimum) and a repeat panel somewhere around 4 to 8 weeks in, since that's the window most trial protocols and clinical practice use to gauge initial response ^{[2] [3]}. Expect a daily or near-daily oral tablet rather than injections, refrigeration questions aside (some compounded formulations have specific storage guidance depending on the pharmacy; check does Enclomiphene Direct need to be refrigerated if that's come up for your prescription). Expect testosterone to rise gradually rather than spike the way it can with injectable esters, since the mechanism depends on the pituitary ramping up LH/FSH output rather than delivering the hormone directly. Some men respond within a few weeks; others need a dose adjustment after the first labs come back. And expect your prescriber to keep monitoring PSA and hematocrit periodically, the same as they would for TRT, because the endpoint (elevated testosterone) carries the same downstream monitoring needs regardless of how you got there.

Frequently asked questions

Is enclomiphene FDA-approved?

No. Enclomiphene was developed under the brand name Androxal by Repros Therapeutics and went through FDA review, but the application did not result in approval. Searching FDA's Drugs@FDA database confirms there is no approved enclomiphene product; what's available today is compounded through licensed pharmacies under a prescription, not sold as an approved manufactured drug.

What's the difference between enclomiphene and clomiphene?

Clomiphene citrate is a mixture of two isomers, enclomiphene and zuclomiphene, at roughly a 62:38 ratio. Enclomiphene is the isomer responsible for most of the estrogen-receptor-blocking activity at the hypothalamus that drives the testosterone-raising effect; zuclomiphene clears more slowly and has a more mixed activity profile linked to some side effects.

Does enclomiphene really preserve fertility better than testosterone therapy?

Trial data show enclomiphene preserves LH, FSH, and testicular volume markers better than testosterone gel, which is the physiological basis for a fertility advantage. But no large trial has tracked actual pregnancy rates or years-long semen outcomes specifically for enclomiphene, so the fertility-preservation claim is mechanism-and-hormone-backed, not outcome-proven at scale.

What animal studies were done on enclomiphene before human trials?

Rodent and rabbit studies in the 1960s and 70s first identified that clomiphene's two isomers behave differently, with enclomiphene acting mainly as an estrogen receptor antagonist. Some canine pharmacology work supported the hypothalamic-pituitary mechanism further. These studies established plausibility, not human dosing or long-term safety.

Why did Androxal (enclomiphene) fail to get FDA approval?

Repros Therapeutics' regulatory filings pointed to FDA concerns about the completeness of long-term safety data and how durably the testosterone response held up across the phase 3 program. The company did not successfully resubmit before shelving the program, leaving enclomiphene without an approved label.

Can women take enclomiphene?

Enclomiphene has been studied almost exclusively in men within the Androxal program; clomiphene citrate (the isomer mixture) is the FDA-approved drug for female ovulation induction, not enclomiphene alone. Enclomiphene is not an approved or established treatment for female infertility.

How long does it take for enclomiphene to raise testosterone?

In clinical trials, meaningful testosterone increases were typically seen within 4 to 6 weeks of starting therapy, with most prescribers rechecking labs in that window. Full stabilization can take a bit longer depending on starting hormone levels and dose.

Is compounded enclomiphene legal?

Yes, when prescribed by a licensed provider and dispensed by a licensed compounding pharmacy operating under state pharmacy law and FDA's compounding framework (503A or 503B). It's legal, but it's a different regulatory category than an FDA-approved manufactured drug with a standardized label.

Does enclomiphene shrink the testicles like TRT can?

Trial data show enclomiphene largely avoids the testicular volume reduction seen with exogenous testosterone, because it raises rather than suppresses LH and FSH. This is one of the clearest human-data-backed differences between the two approaches.

What side effects showed up in enclomiphene human trials?

Reported effects include headache, mood changes, occasional liver enzyme elevation, and less commonly visual disturbances, generally at lower rates than seen historically with clomiphene. Prescribers typically monitor PSA and hematocrit alongside testosterone, since those apply to any therapy that raises testosterone levels.

Is there long-term safety data on enclomiphene?

Not at the scale of large trials like TRAVERSE, which studied testosterone therapy and cardiovascular outcomes over years in thousands of men. Enclomiphene's human trial follow-up is generally under a year, so multi-year cardiovascular and fertility outcome data simply doesn't exist yet.

How is enclomiphene different from hCG for preserving fertility?

Enclomiphene works upstream at the hypothalamus, raising the body's own LH and FSH output; hCG mimics LH directly at the testes. Both can help preserve testicular function versus TRT alone, but hCG requires injections and is often used alongside TRT, while enclomiphene is an oral standalone option.

Sources

1. NCBI Bookshelf/StatPearls, Clomiphene physiology and isomer pharmacology: Clomiphene is a mixture of enclomiphene and zuclomiphene isomers with distinct receptor activity
2. ClinicalTrials.gov, Repros Therapeutics enclomiphene phase 3 trial record: Phase 3 trial design and endpoints for enclomiphene citrate (Androxal) in hypogonadal men
3. Journal of Sexual Medicine, Kaminetsky et al. 2012 enclomiphene vs testosterone gel study: Enclomiphene raised testosterone and LH while preserving markers of testicular function compared to testosterone gel, which suppressed LH
4. FDA, Drugs@FDA database search: No FDA-approved drug application exists for enclomiphene as a standalone product
5. U.S. Securities and Exchange Commission, Repros Therapeutics 10-K filing: Repros Therapeutics regulatory filings document FDA review history and non-approval of Androxal
6. New England Journal of Medicine, TRAVERSE trial (Lincoff et al. 2023): Large-scale cardiovascular safety data exists for testosterone replacement therapy but not at equivalent scale for enclomiphene